Predator Oil & Gas (PRD), the Jersey-based Oil and Gas Company with near-term hydrocarbon operations and production focussed on Morocco and Trinidad, announced an update on the preliminary MOU-5 drilling results in the Guercif Licence onshore Morocco.
PRD said “The results of the MOU-5 drilling programme have unlocked a new Jurassic play-opening trend never before tested in the Guercif Basin. A helium show has provided the impetus to further assess the helium potential of the MOU-5 structure. Confirmation of our pre-drill play concept and seismic inversion modelling work based on limited 2D seismic data allows for the acquisition of more focussed additional seismic data to clarify the updip potential.”
Comment: One can understand the frustration that PRD may have had with its share price of late, as the market these days does not have a grain of salt’s worth of being forward looking. As MOU-5 is further revealed one would expect this situation to be reversed very positively in the company’s favour.
Great Southern Copper (GSCU), the company focused on copper-gold-silver exploration in Chile, reported further exceptional assay results from Phase I drilling at the Mostaza Mine, Cerro Negro. GSCU said “These outstanding results confirm that high grade Cu-Ag mineralisation is continuing to depth and along strike and demonstrate that the former Mostaza mine has the potential to be a high-grade high-value Cu-Ag deposit.”
Comment: Something of a victory lap for GSCU and Mostaza, as we can also tell from the ongoing rise in the share price, showing how the market continues to re-rate the company.
Ondine Biomedical (OBI) said that at the 25th Annual Scientific Conference of the Canadian Spine Society, researchers from the University of Sherbrooke presented findings from a year-long retrospective quality of care study confirming the safety and efficacy of Steriwave® nasal photodisinfection therapy (aPDT) in spine surgery patients. Data from the podium presentation demonstrated that patients who received presurgical Steriwave nasal photodisinfection had 78.8% fewer surgical site infections.
Comment: Further evidence, as if we needed it, of the breakthrough represented by Steriwave, something which the market is yet to catch up on, hence today’s RNS contributes well.
Beeks Financial Cloud Group (BKS), a cloud computing and connectivity provider for financial markets, announce its unaudited results for the six months ended 31 December 2024. Revenues increased by 22% to £15.79m (H1 2024: £12.96m). Gross profit up by 21% to £6.03m (H1 2024: £4.99m). Underlying EBITDA increased by 25% to £5.74m (H1 2024: £4.61m). Underlying profit before tax up 37% to £1.89m (H1 2024: £1.38m).
Comment: Not something that one might have intuitively thought, but as commented on X, a £170m seems rather rich for BKS. This is the result of all the “smart” money funnelling into the better small cap situations in a bear market.
Hemogenyx Pharmaceuticals (HEMO) announced the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. HEMO said “This marks a significant step forward in the Company’s clinical development program and underscores the progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options.”
Comment: Sometimes HEMO gives the impression of being the longest science experiment in history. It is to be hoped that something substantive is finally the result.
Emmerson (EML), the Moroccan focused potash development company, announced that, further to the announcement on 2 January 2025, the Company has drawn down the first tranche of funding under the Capital Provision Agreement which will provide the Company with up to US$11,000,000 in both litigation finance capital and working capital.
Comment: As most of us are well aware, lawyers are not big on losing money. This fact, and the way that shares of EML have been on the front foot since the turn of the year since litigation funding was delivered, underlining hopes for a positive result in Morocco.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
